Editor-in-Chief, Deputy Editor 2017-2019

 

Editor-in-Chief:

Tom MOREELS

 

Deputy Editor:

Nicolas LANTHIER

 

More news.

Position statements


"Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD) "


Price: €10,00

Biosimilars are biological drugs which are similar to the authorized biologics (“reference product”) but not identical (1). The European legislation has offered since 2006 a legal framework for biosimilars. The concept and methodology of the comparative investigations are further treated in the guidelines of the European Medicines Agency (EMA)(1). A biosimilar is only authorized when it can be stated with appropriate certainty that its variability and the differences with the reference medicinal product will not have a relevant influence on the safety or efficacy. EMA has approved a first one biosimilar to infliximab, namely CT-P13 and marketed with two brand names Remsima (2) and Inflectra (3), on the basis of two randomized controlled trials (RCT) in Rheumathoid Arthritis (RA) and Ankylosing Spondylitis (AS) (4, 5). More recently, a second biosimilar SB2, Flixabi (6), has been approved/registered and has also been evaluated in RA (7). [Product Details...]


The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease


Price: €10,00

Non-Alcoholic Fatty Liver Disease (NAFLD) is highly prevalent and associated with considerable liver-related and non-liverrelated morbidity and mortality. There is, however, a lot of uncertainty on how to handle NAFLD in clinical practice. The current guidance document, compiled under the aegis of the Belgian Association for the Study of the Liver by a panel of experts in NAFLD, from a broad range of different specialties, covers many questions encountered in daily clinical practice regarding diagnosis, screening, therapy and follow-up in adult and paediatric patients. Guidance statements in this document are based on the available evidence whenever possible. In case of absence of evidence or inconsistency of the data, guidance statements were formulated based on consensus of the expert panel. This guidance document is intended as a help for clinicians (general practitioners and all involved specialties) to implement the most recent evidence and insights in the field of NAFLD within a Belgian perspective. (Acta gastroenterol. belg., 2018, 81, 55-81). [Product Details...]


  • «« Start
  • « Prev
  • 1
  • Next »
  • End »»
Results 1 - 2 of 2